Galantamine-associated nightmares and anxiety

Consultant Pharmacist

Volumn 28, Issue 4, 2013, Pages 243-246

  Corbo, Jason M ^a,b   Brown, Jamie N ^b   Moss, Jason M ^b,c  

^a St Margaret Memorial Hospital   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c CAMPBELL UNIVERSITY   (United States)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Anxiety; Dementia; Dreams; Galantamine; Nightmare

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CALCIUM; CREATININE; CYANOCOBALAMIN; GALANTAMINE; HYDROCHLOROTHIAZIDE; LOSARTAN; OMEPRAZOLE; SIMVASTATIN; THYROTROPIN; VITAMIN D;

AGED; ALZHEIMER DISEASE; ANXIETY; ARTICLE; CASE REPORT; CATARACT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DIZZINESS; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; FLUSHING; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORIENTATION; PROSTATE HYPERTROPHY; SHORT TERM MEMORY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; ANXIETY; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DREAMS; GALANTAMINE; HUMANS; MALE; QUALITY OF LIFE; RECURRENCE;

EID: 84876166829     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2013.243     Document Type: Article

References (15)

1. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012;8: 131-68.
2. Rabins PV, Blacker D, Rovner BW et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Am J Psychiatry 2007; 164: 5-56.
3. Razadyne ER/Razadyne (package insert). Titusville, NJ: Ortho- McNeil-Janssen Pharmaceuticals, Inc; 2008.
4. Spoormaker VI, Schredl M, van den Bout J. Nightmares: from anxiety symptom to sleep disorder. Sleep Med Rev 2006;10: 19-31.
5. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: 239-45.
6. Aurora RN, Zak RS, Auerbach SH et al. Best practice guide for the treatment of nightmare disorder in adults. J Clin Sleep Med 2010;6: 389-401.
7. Iraqi A, Hughes TL. An unusual case of nightmares with galantamine. J Am Geriatr Soc 2009;57: 565.
8. Stahl SM, Markowitz JS, Papadopoulos G et al. Examination of nighttime sleep-related problems during double-blind, placebocontrolled trials of galantamine in patients with Alzheimer's disease. Curr Med Res Opin 2004;20: 517-24.
9. Nieoullon A, Bentué-Ferrer D, Bordet R et al. Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine. Curr Med Res Opin 2008;24: 3357-67.
10. Aricept (package insert). Woodcliff Lake, NJ: Eisai Co., Ltd; 2010.
11. Ross JS, Shua-Haim Jr. Aricept-induced nightmares in Alzheimer's disease: 2 case reports. J Am Geriatr Soc 1998;46: 119-20.
12. Dunn NR, Pearce GL, Shakir SAW. Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol 2000;14: 406-8.
13. Wilkinson DG, Passmore AP, Bullock R et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56: 441-6.
14. Exelon Patch (package insert). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
15. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry 2001;49: 289-99.